No Data
No Data
No Data
No Data
No Data
Mid-Cap Corcept Therapeutics Reveals Data From Hormonal Disorder Study, FDA Application Submission Expected This Quarter
Monday, Corcept Therapeutics Incorporated (NASDAQ:CORT) released results from the open-label portion of the pivotal Phase 3 GRACE trial of its proprietary selective cortisol modulator relacorilant in
Benzinga12:36 ET
Corcept Falls After Phase 3 Results on Cushing's Candidate Doesn't Include Some Data
Seeking AlphaApr 22 11:22 ET
Express News | Corcept Therapeutics Inc: Relacorilant Was Well Tolerated
Moomoo 24/7Apr 22 08:05 ET
Express News | Corcept Therapeutics: Remain on Track to Submit Our Nda This Qtr
Moomoo 24/7Apr 22 08:05 ET
Express News | Corcept Therapeutics Inc: No Cases of Relacorilant-Induced Endometrial Hypertrophy With or Without Vaginal Bleeding Were Seen
Moomoo 24/7Apr 22 08:04 ET
Express News | Corcept Therapeutics: Statistically Significant Improvements in Hypertension, Hyperglycemia and Other Key Secondary and Exploratory Endpoints
Moomoo 24/7Apr 22 08:03 ET
No Data
No Data